| Literature DB >> 29144445 |
Irene Gouvinhas1, Nelson Machado2, Carla Sobreira3, Raúl Domínguez-Perles4, Sónia Gomes5,6, Eduardo Rosa7, Ana I R N A Barros8.
Abstract
Olive oil displays remarkable organoleptic and nutritional features, which turn it into a foodstuff appreciated by consumers, and a basic component of the Mediterranean diet. Indeed, the noticed benefits of including olive oil in the diet have been assigned to the presence of diverse bioactive compounds with different molecular structures. These compounds confer a wide range of biological properties to this food matrix, including the prevention of distinct human diseases as well as the modulation of their severity. The most relevant bioactive compounds present in olive oil correspond to benzoic and cinnamic acids, phenolic alcohols and secoiridoids, and also flavonoids. Over the last decades, several studies, devoted to gaining a further insight into the relative contribution of the separate groups and individual compounds for their biological activities, have been conducted, providing relevant information on structure-activity relationships. Therefore, this paper critically reviews the health benefits evidenced by distinct phenolic compounds found in olive oils, thus contributing to clarify the relationship between their chemical structures and biological functions, further supporting their interest as essential ingredients of wholesome foods.Entities:
Keywords: Olea europaea L.; biological activity; mediterranean diet; molecular structure; phenolic compounds
Mesh:
Substances:
Year: 2017 PMID: 29144445 PMCID: PMC6150410 DOI: 10.3390/molecules22111986
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Ripening index: 0, skin colour deep green; 1, skin colour yellow green; 2, Skin colour green with reddish spots on
Phenolic alcohols and acetate derivatives described in olives and virgin olive oil.
| Phenolic Class | Compound | Substituent | Reference | ||||
|---|---|---|---|---|---|---|---|
| R2 | R3 | R4 | R5 | R6 | |||
| Benzoic acids | 3-Hydroxybenzoic acid | -H | -OH | -H | -H | -H | [ |
| 4-Hydroxybenzoic acid | -H | -H | -OH | -H | -H | [ | |
| Protocatechuic acid | -H | -OH | -OH | -H | -H | [ | |
| 2,4-Dihydroxybenzoic acid | -OH | -H | -OH | -H | -H | [ | |
| 2,6-Dihydroxybenzoic acid | -OH | -H | -H | -H | -OH | [ | |
| Gallic acid | -H | -OH | -OH | -OH | -H | [ | |
| Gentisic acid | -OH | -H | -H | -OH | -H | [ | |
| Vanillic acid | -H | -OCH3 | -OH | -H | -H | [ | |
| Syringic acid | -H | -OCH3 | -OH | -OCH3 | -H | [ | |
| Cinnamic acids | -OH | -H | -H | -H | -H | [ | |
| -H | -OH | -H | -H | -H | [ | ||
| -H | -H | -OH | -H | -H | [ | ||
| Caffeic acid | -H | -OH | -OH | -H | -H | [ | |
| Hydroxycaffeic acid | -OH | -OH | -OH | -H | -H | [ | |
| Ferulic acid | -H | -OCH3 | -OH | -H | -H | [ | |
| Sinapic acid | -H | -OCH3 | -OH | -OCH3 | -H | [ | |
| Chlorogenic acid | -H | -H | -H | -H | -H | [ | |
| Hydroxycinnamic acid derivatives | Verbascoside | - | - | - | - | - | [ |
| Phenylacetic acids | -H | -H | -OH | -H | -H | [ | |
| 3,4-Dihydroxyphenylacetic acid | -H | -OH | -OH | -H | -H | [ | |
| Homovanillic acid | -H | -OCH3 | -OH | -H | -H | [ | |
| Other phenolic acid | 3-(3,4-Dihydroxyphenyl)propanoic acid | - | - | - | - | - | [ |
| Phenolic alcohols | Tyrosol ( | -H | -H | -OH | -H | -H | [ |
| Hydroxytyrosol ( | -H | -OH | -OH | -H | -H | [ | |
| 3,4-Dihydroxyphenyl)ethanol-glucoside ( | -H | -H | -H | -H | -H | [ | |
| Hydroxytyrosol acetate ( | -H | -OH | -OH | -H | -H | [ | |
| Tyrosol acetate ( | -H | -H | -OH | -H | -H | [ | |
Secoiridoids, lignans, hydroxy-isochromans and flavonoids described in olives and virgin olive oil.
| Phenolic Class | Compound | Substituent | Reference | |||||
|---|---|---|---|---|---|---|---|---|
| R1 | R2 | R3 | R4 | R5 | R6 | |||
| Seicoiridoids | Decarboxymethyloleuropein aglycon | -OH | - | - | - | - | - | [ |
| Oleocanthal | -H | - | - | - | - | - | [ | |
| Oleuropein aglycon | -OH | -OH | - | - | - | - | [ | |
| Ligstroside aglycon | -H | -OH | [ | |||||
| Aldehydic form of oleuropein aglycon | -OH | -OH | - | - | - | - | [ | |
| Aldehydic form of ligstroside aglycon | -H | -OH | - | - | - | - | [ | |
| Oleuropein | -OH | -O-Glc | - | - | - | - | [ | |
| Lignans | (+)-Pinoresinol | -H | - | - | - | - | - | [ |
| (+)-1-Acetoxypinoresinol | -OCOCH3 | - | - | - | - | - | [ | |
| (+)-1-Hydroxypinoresinol | -OH | - | - | - | - | - | [ | |
| Hydroxy-isochromans | 1-Phenyl-6,7-dihydroxyisochroman | -H | -H | - | - | - | - | [ |
| 1-(3’-Methoxy-4’-hydroxy)phenyl-6,7-dihydroxyisochroman | -OH | -OCH3 | - | - | - | - | [ | |
| Luteolin-5-glucoside | -OH | -H | -Glc | |||||
| Flavones | Apigenin | -H | -H | -H | - | - | - | [ |
| Apigenin-7-glucoside | -H | -Glc | -H | |||||
| Apigenin-7-rutinoside | -H | -Rut | -H | |||||
| Luteolin | -OH | -H | -H | - | - | - | [ | |
| Luteolin-7-glucoside | -OH | -Glc | -H | |||||
| Luteolin-5-glucoside | -OH | -H | -Glc | |||||
| Flavonols | Quercetin | - | - | -OH | - | - | - | [ |
| Quercetin-3-rutinoside | - | - | -Rut | - | - | - | [ | |
| (+)-Taxifolin | - | - | - | - | - | - | [ | |
| Other phenolic compounds | 3,4-Dihydroxyphenylglycol | - | - | - | - | - | [ | |
Rut, rutinoside; Glc, glucoside.
HPLC procedures in separation of different classes of phenolic compounds.
| Stationary Phase | Mobile Phase | Flow Rate (mL/min) | Compounds Identified | Reference | ||||
|---|---|---|---|---|---|---|---|---|
| A | B | C | ||||||
| Luna C18 | 0.1% Formic acid 99.9% Water | 95% MeCN | - | 30 | 0.40 | 210–600 | Phenolic acids; Phenolic alcohols; Secoiridoids; Lignans; Flavonoids. | [ |
| Kinetex C18 | 100% Water | 100% Acetonitrile | 100% Methanol | 40 | 1.25 | - | Phenolic acids; Phenolic alcohols; Secoiridoids; Lignans. | [ |
| Luna C18 | 0.1% Acetic acid 99.9% Water | 100% Acetonitrile | - | - | 0.60 | 275 | Phenolic acids; Phenolic alcohols; Secoiridoids. | [ |
| Zorbax Eclipse Plus RP-C18 | 0.25% Acetic acid 99.75% Water | 100% Methanol | - | RT Z | 0.80 | - | Secoiridoids; Lignans; | [ |
| Inertsil ODS-3 | 2% Formic acid 98% Water | 100% Methanol | - | 22 | 0.85 | 240, 280, 320 | Phenolic acids; Phenolic alcohols; Flavonoids. | [ |
| Zorbax SB-C18 | 5% Acetic acid 95% Water | 100% Methanol | 100% Acetonitrile | 30 | 1.00 | 240, 280, 335 | Phenolic acids; Phenolic alcohols; Flavonoids. | [ |
| Hypersil Gold QRP-18 | 100% Formic acid | 100% Acetonitrile | 100% Methanol | 30 | 0.80 | 240, 280, 330 | Phenolic acids; Phenolic alcohols; Flavonoids; | [ |
| Spherisorb S3 ODS2 | 5% Acetic acid 95% Water | 100% Methanol | 100% Acetonitrile | 30 | 1.00 | 280 | Phenolic acids; Phenolic alcohols; Secoiridoids; Lignans; Flavonoids. | [ |
| Zorbax SB-C18 | 0.2% Acetic acid | 100% Acetonitrile | - | 30 | 0.40 | - | Phenolic acids; Phenolic alcohols; Secoiridoids; Lignans. | [ |
| XDB-C18 | 0.5% Acetic acid | 99.5% Acetonitrile | - | 15 | 0.60 | 254, 280, 310, 350 | Phenolic acids; Phenolic alcohols; Secoiridoids; | [ |
| Zorbax C18 | 0.5% Acetic acid | 100% Acetonitrile | - | 30 | 1.50 | 240, 280 | Phenolic alcohols; Secoiridoids; Flavonoids; | [ |
| Hypersil MOS | 0.5% Acetic acid | 99.5% Acetonitrile | - | 25 | 0.50 | 255, 260, 275, 280, 310, 320, 325, 340, 350 | Phenolic acids; Phenolic alcohols; Flavonoids | [ |
Z Room temperature. Mobile phase: Terms A, B, and C refer to the different phases used during gradient.
Figure 2Scheme of the routes involved in the bioavailability and excretion of dietary phenolic compounds.
Studied effects of Extra Virgin Olive Oil (EVOO) in vivo.
| Compound/Matrix | Activity | Model and Dosis/Intake | Significant Effects | Reference |
|---|---|---|---|---|
| Hydroxytyrosol | Reduction of oxidative stress | Humans, intake of 50.0 mL of oil with 4.2 mg of hydroxytyrosol and 39.5 mg of oleuropein | ~35% reduction in the urinary excretion of 8-iso-PGF2α | [ |
| Oleuropein | ||||
| Anti-tumour activity; prevention of skin and breast cancer | Hairless Mice, intake of oleuropein extract | Significantly reduced the incidence and growth of tumours | [ | |
| Reduction of plasmatic levels of free cholesterol | Rabbits, standard food supplemented with olive oil 10% ( | Observed oleuropein aglycone plasmatic levels of 0.892 µM, and LDL increase of 90% | [ | |
| Protection against heart damage | Ischemia reperfusion in rats, pre-treatment with 20 µg g−1 before ischemia | Significant time-dependent decrease in creatine kinase and reduction of glutathione release | [ | |
| Hypoglycemic and antioxidant effect | New Zealand male rabbits, diabetes induced, 20 mg kg−1 body weight of oleuropein | Significant decline in plasma and erythrocyte MDA reached at week 10 | [ | |
| Oleanolic acid | Inhibition of cancer proliferation | Mice, HepG2 cells subcutaneously implanted in mice, intraperitoneal injection of OA | 75 or 150mg/kg/day led to tumour inhibitory ratios of 31.72% and 57.24%, respectively | [ |
| Oleocanthal | Suppression of tumorigenicity | Chicken embryos, implantation of HT29 tumoral cells | ~50% reduction of tumour area by treatment with 50 µg/mL | [ |
| EVOO | Inhibition of the atherosclerosis process | Humans, daily consumption of 50.0 mL of olive oil | Significant decrease in the inflammatory markers TXB2 and LTB4 | [ |
| EVOO | Improve lipid metabolism | Male Wistar rats, cholesterol-free or 1% cholesterol diets, 10 g/100 g EVOO | Reduction of increase in plasma lipids: TC (23.6%), LDL-C (39.3%), TG (19.3%), and TC in liver (36.0%) | [ |
| Increase plasma antioxidant potential | 20.6% increase in TRAP, and 23.2% decrease in MDA |
TC—Total Cholesterol; LDL-C—LDL-cholesterol; TG—triglycerides; TRAP—Total radical-trapping antioxidative potential; TC—Plasma total cholesterol; MDA—Malondialdehyde.
Studied effects of EVOO in vitro.
| Compound | Activity | Model | Effective Concentration | Reference |
|---|---|---|---|---|
| Oleuropein | Scavenge hypochlorous acid in neutrophils | Xantine-xantine oxidase | 14.3 µM (EC50) | [ |
| Hydroxytyrosol | 9.1 µM (EC50) | |||
| Oleuropein | 1 PMN ± PMA | 29.3 µM (EC50) | ||
| Hydroxytyrosol | 3.2 µM (EC50) | |||
| Oleuropein | Scavenge nitric oxide | Scavenging of nitric oxide generated from 5 mm sodium nitroprusside | ~75 µM (EC50) | [ |
| Caffeic acid | ||||
| Hydroxytyrosol | ||||
| Oleuropein | (67.2–92.4%) at 1.0 mm | |||
| Caffeic acid | ||||
| Hydroxytyrosol | ||||
| Avoiding low-density lipoprotein (LDL) oxidation | Inhibition of LDL copper-induced oxidation | ~70% inhibition by 10.0 µM | [ | |
| Oleuropein | Atheroprotection | Inhibition of VCAM-1 | 15.0 µM (IC50) | [ |
| VCAM-1 mRNA levels | 60% reduction by 30 µM | |||
| Hydroxytyrosol | 25% reduction by 30 µM | |||
| Erythrodiol | Anti-proliferative | HT-29 (colon adenocarcinoma) | 48.8 ± 3.7 µM (EC50) | [ |
| Apoptotic activity | HT-29, Caspase-3-like activity | 50, 100, and 150 µM—3.2, 4.8 and 5.2 × increase, respectively | ||
| Anti-proliferative | MCF-7 | ~90% inhibition by 100 µM (24 h) | [ | |
| Uvaol | ~60% inhibition by 100 µM (24 h) | |||
| Oleanolic acid | ~85% inhibition by 100 µM (24 h) | |||
| Inducing apoptotic cell death | HCC (hepatocellular carcinoma) HepG2 | Proliferation decrease of 46.5% by 40 μM (24 h) | [ | |
| Luteolin-7- | Anti-proliferative | MCF-7 | 40.85 ± 5.01 µM (IC50) | [ |
| Oleuropein | 12.00 ± 0.62 µM (IC50) | |||
| Hydroxytyrosol | 24.86 ± 8.15 µM (IC50) | |||
| Hydroxytyrosol acetate | 28.67 ± 8.10 µM (IC50) | |||
| Luteolin-7- | T-24 (bladder carcinoma cells) | 11.35 ± 0.32 µM (IC50) | ||
| Hydroxytyrosol | 12.39 ± 2.20 µM (IC50) | |||
| Hydroxytyrosol acetate | 23.32 ± 0.38 µM (IC50) | |||
| Oleuropein | 7.59 ± 1.80 µM (IC50) | |||
| Reduction of inflammatory angiogenesis | HUVEC (human vascular endothelial cells), Matrigel assay | Decrease of 40% by 10 µM | [ | |
| Hydroxytyrosol | Decrease of 55% by 10 µM | |||
| Maslinic acid | HT-29 (colon adenocarcinoma) | 28.8 ± 0.9 µg mL−1 (EC50) | [ | |
| Squalene | Decrease of radical oxygen species level | MCF10A (breast epithelial cells), H2O2 assay | ~50% reduction by 50 µM (24 h) | [ |
| Oleocanthal | Inducing apoptotic cell death | ARH-77 (multiple myeloma cell line) | Proliferation decrease of ~80% by 50 μM (24 h) | [ |
| Inhibition of carcinogenesis | JB6 Cl41 (cell line sensitive to carcinogenesis) | 3 µM inhibits the expression of p-ERK 1/2, and P-p90rsk | [ | |
| Inducing apoptotic cell death | SK-BR-3 (Human breast cancer cell line) | Proliferation decrease of ~10% by 15 µM | ||
| HCT-116 (Human colon colorectal carcinoma) | Proliferation decrease of ~70% by 15 µM | |||
| Inhibition of metastatic process | MCF7 (nonmetastatic human breast cancer) | 18 µM (IC50) | [ | |
| MDA-MB-231(highly metastatic human breast cancer) | 15 µM (IC50) | |||
| PC-3 (human prostate cancer) | 20 µM (IC50) | |||
| Anti-inflammatory activity | Inhibition of MIP-1α in J774 macrophages | ~50% inhibition by 50 µM (24 h) | [ | |
| Inhibition of IL-6 in J774 macrophages | ~60% inhibition by 50 µM (24 h) | |||
| Inhibition of MIP-1α in ATDC5 chondrocytes | ~90% inhibition by 50 µM (24 h) | |||
| Inhibition of IL-6 in ATDC5 chondrocytes | ~75% inhibition by 50 µM (24 h) | |||
| Oleocanthal (−) | Anti-inflammatory activity | COX1 inhibition | 56.1 ± 3.2% inhibition by 25 µM | [ |
| Oleocanthal (+) | 68.0 ± 15.2% inhibition by 25 µM | |||
| Oleocanthal (−) | COX2 inhibition | 56.6 ± 9.5% inhibition by 25 µM | ||
| Oleocanthal (+) | 41. 3± 15.9% inhibition by 25 µM |
1 PMN, human polymorphonuclear neutrophils; PMA, phorbol-12-myristate-13 acetate.
Figure 3Biological activities of phenolic compounds present in olive oil demonstrated in humans.